Positive News SentimentPositive NewsNASDAQ:FRLN Freeline Therapeutics (FRLN) Stock Forecast, Price & News $4.33 +0.42 (+10.74%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$3.78▼$4.4450-Day Range$3.16▼$5.1052-Week Range$2.11▼$12.00Volume53,212 shsAverage Volume167,587 shsMarket Capitalization$18.79 millionP/E RatioN/ADividend YieldN/APrice Target$13.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Freeline Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside210.3% Upside$13.25 Price TargetShort InterestHealthy2.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.04) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector673rd out of 963 stocksBiological Products, Except Diagnostic Industry106th out of 159 stocks 3.3 Analyst's Opinion Consensus RatingFreeline Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.25, Freeline Therapeutics has a forecasted upside of 210.3% from its current price of $4.27.Amount of Analyst CoverageFreeline Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.50% of the float of Freeline Therapeutics has been sold short.Short Interest Ratio / Days to CoverFreeline Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Freeline Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFreeline Therapeutics does not currently pay a dividend.Dividend GrowthFreeline Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FRLN. Previous Next 2.7 News and Social Media Coverage News SentimentFreeline Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Freeline Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for FRLN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Freeline Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Freeline Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.90% of the stock of Freeline Therapeutics is held by insiders.Percentage Held by Institutions46.26% of the stock of Freeline Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Freeline Therapeutics are expected to decrease in the coming year, from ($1.04) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Freeline Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Freeline Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFreeline Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Freeline Therapeutics (NASDAQ:FRLN) StockFreeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.Read More FRLN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FRLN Stock News HeadlinesAugust 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Freeline Therapeutics Holdings (FRLN)August 17, 2023 | finance.yahoo.comFreeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Earnings Call TranscriptSeptember 27, 2023 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! August 16, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Freeline TherapeuticsAugust 16, 2023 | finance.yahoo.comQ2 2023 Freeline Therapeutics Holdings PLC Earnings CallAugust 15, 2023 | seekingalpha.comFreeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62MAugust 15, 2023 | finanznachrichten.deFreeline Therapeutics Holdings plc: Freeline Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 15, 2023 | finance.yahoo.comFreeline Reports Second Quarter 2023 Financial Results and Business HighlightsSeptember 27, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 14, 2023 | benzinga.comFreeline Therapeutics's Earnings: A PreviewAugust 8, 2023 | finance.yahoo.comFreeline Therapeutics to Host Second Quarter 2023 Financial Results CallJuly 25, 2023 | finance.yahoo.comFreeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher DiseaseJuly 20, 2023 | thestreet.comFreeline Therapeutics Holdings plcJuly 13, 2023 | benzinga.comFreeline Therapeutics Holdings Shares Halted On Circuit Breaker To The Upside, Up 53.1%July 13, 2023 | finance.yahoo.comEstimating The Fair Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)June 26, 2023 | tmcnet.comFreeline Announces First Patient Dosed with Its NovelJune 26, 2023 | finance.yahoo.comFreeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s DiseaseJune 13, 2023 | finance.yahoo.comFreeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowJune 7, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Freeline Therapeutics Holdings (FRLN)June 2, 2023 | finance.yahoo.comFreeline to Present at 2023 Jefferies Healthcare ConferenceMay 30, 2023 | finanznachrichten.deFreeline Therapeutics Holdings plc: Freeline Reports First Quarter 2023 Financial Results and Business HighlightsMay 30, 2023 | finance.yahoo.comFreeline Reports First Quarter 2023 Financial Results and Business HighlightsMay 22, 2023 | finance.yahoo.comFreeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher DiseaseMay 14, 2023 | investing.comFreeline (FRLN) Earnings Dates & ReportsMay 12, 2023 | finanznachrichten.deFreeline Therapeutics Holdings plc: Freeline Completes ADS Ratio ChangeMay 12, 2023 | finance.yahoo.comBoth private equity firms who control a good portion of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) along with institutions must be dismayed after last week's 11% decreaseMay 12, 2023 | finance.yahoo.comFreeline Completes ADS Ratio ChangeSee More Headlines Receive FRLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FRLN Company Calendar Last Earnings8/15/2023Today9/27/2023Next Earnings (Estimated)11/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FRLN CUSIPN/A CIK1810031 Webwww.freeline.life Phone44-0-14-3890-6870FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.25 High Stock Price Forecast$30.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+211.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($8.3990) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-129.10% Return on Assets-85.49% Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.07 per share Price / Book0.35Miscellaneous Outstanding Shares4,340,000Free Float4,259,000Market Cap$18.49 million OptionableNot Optionable Beta0.68 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Michael J. Parini J.D. (Age 48)CEO & Exec. Director Comp: $2.16MMr. Paul M. Schneider (Age 52)CFO & Director Dr. Henning R. Stennicke Ph.D. (Age 55)Chief Scientific Officer Ms. Nicole Jones SPHR (Age 52)Chief People Officer Mr. James Bircher (Age 55)Chief Technical Operations Officer Dr. Pamela Foulds M.D. (Age 53)Chief Medical Officer Ms. Naomi AokiSr. VP of Corp. Communications & Investor RelationsMs. Amy J. Spandau (Age 48)Interim Head of Fin. More ExecutivesKey CompetitorsHarpoon TherapeuticsNASDAQ:HARPBrainstorm Cell TherapeuticsNASDAQ:BCLIMicrobot MedicalNASDAQ:MBOTGenetic TechnologiesNASDAQ:GENEAcorda TherapeuticsNASDAQ:ACORView All CompetitorsInstitutional OwnershipCHI Advisors LLCSold 4,707,753 shares on 8/22/2023Ownership: 0.499%Renaissance Technologies LLCSold 208,740 shares on 8/11/2023Ownership: 0.504%Northern Trust CorpBought 15,659 shares on 8/11/2023Ownership: 0.361%Syncona Portfolio LtdSold 20,531,112 shares on 7/27/2023Ownership: 33.791%Harbor Capital Advisors Inc.Sold 97,022 shares on 7/11/2023Ownership: 0.247%View All Institutional Transactions FRLN Stock - Frequently Asked Questions Should I buy or sell Freeline Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FRLN shares. View FRLN analyst ratings or view top-rated stocks. What is Freeline Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued twelve-month price objectives for Freeline Therapeutics' stock. Their FRLN share price forecasts range from $3.00 to $30.00. On average, they anticipate the company's stock price to reach $13.25 in the next year. This suggests a possible upside of 211.0% from the stock's current price. View analysts price targets for FRLN or view top-rated stocks among Wall Street analysts. How have FRLN shares performed in 2023? Freeline Therapeutics' stock was trading at $7.1265 on January 1st, 2023. Since then, FRLN stock has decreased by 40.2% and is now trading at $4.26. View the best growth stocks for 2023 here. When is Freeline Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023. View our FRLN earnings forecast. How were Freeline Therapeutics' earnings last quarter? Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($3.62) by $3.41. The business earned $0.62 million during the quarter. When did Freeline Therapeutics' stock split? Freeline Therapeutics shares reverse split on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Freeline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME). When did Freeline Therapeutics IPO? (FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Freeline Therapeutics' stock symbol? Freeline Therapeutics trades on the NASDAQ under the ticker symbol "FRLN." Who are Freeline Therapeutics' major shareholders? Freeline Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Syncona Portfolio Ltd (33.79%), Renaissance Technologies LLC (0.50%), CHI Advisors LLC (0.50%), Northern Trust Corp (0.36%) and Harbor Capital Advisors Inc. (0.25%). How do I buy shares of Freeline Therapeutics? Shares of FRLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Freeline Therapeutics' stock price today? One share of FRLN stock can currently be purchased for approximately $4.26. How much money does Freeline Therapeutics make? Freeline Therapeutics (NASDAQ:FRLN) has a market capitalization of $18.49 million. The company earns $-88,970,000.00 in net income (profit) each year or ($8.3990) on an earnings per share basis. How many employees does Freeline Therapeutics have? The company employs 152 workers across the globe. How can I contact Freeline Therapeutics? Freeline Therapeutics' mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The official website for the company is www.freeline.life. The company can be reached via phone at 44-0-14-3890-6870 or via email at ir@freeline.life. This page (NASDAQ:FRLN) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Freeline Therapeutics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.